On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
BUSINESS
Drug Makers Weigh Withdrawal of Unprofitable Drugs, Generic and Innovative Players Alike: Poll
Multiple pharma companies, both generic and brand-name drug manufacturers, are looking at potentially pulling the plug on the business of unprofitable products in Japan in the wake of the FY2025 drug price revision, a Jiho survey found. Such strategic options…
To read the full story
Related Article
- More than Half of Drug Makers’ Top 5 Meds See Flat or Positive Revisions: Poll
March 12, 2025
- Two-Thirds of Drug Makers Discontent with FY2025 Price Revision: Survey
March 11, 2025
- Japan Drug Makers See Varied Impact from 2025 Revision, Foreign Firms Take Hit: Poll
March 10, 2025
- MHLW Unveils New List Prices for FY2025 Revision; Stelara, Januvia Hit by PMP Return
March 7, 2025
BUSINESS
- Keytruda Holds Japan Sales Crown in July-September as Mounjaro Climbs: IQVIA
November 13, 2026
- Genmab Eyes Early Japan Launches for 2 Cancer Blockbuster Hopefuls
November 13, 2026
- Daiichi Sankyo Files Enhertu for Uterine Carcinosarcoma in Japan
November 13, 2026
- MSD Set to Match Beyfortus Price for RSV Antibody Enflonsia if Added to NIP
November 12, 2026
- Takeda Files Zasocitinib for Three Psoriasis Indications in Japan
November 12, 2026
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…